Medical diagnostics firm Alveo Technologies Inc reported on Thursday the election of Johnson Chiang, PhD as its chief technology officer and Rixun Fang, PhD as director of its Assay Development.
In the senior position in the company, Dr Chiang will lead and oversee the company's high-performance product development and commercialiation, with focus on ensuring the technology reaches its full potential, through US FDA approval and into the market.
Previously, Dr Chiang has served as head of Systems Integration and Molecular Biology at Foundation Medicine Inc, held senior management positions at Life Technologies and Thermo Fisher Scientific as well as led molecular diagnostic development projects at Applied MEMS, Applied Biosystems Inc and Cepheid.
Earlier in his career, Dr Fang has successfully led many projects from inception through development and implementation at Applied Biosystems, Life Technologies as well as Thermo Fisher Scientific.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval